Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,258 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Local Disease Clear all
Recruiting Not applicable Interventional

Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients

NCT04933435
View directory record Official record
Conditions
Liver Cancer, Hepatocellular Carcinoma (HCC)
Interventions
Quality of life questionnaires
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

NCT00125255
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Nov 10, 2026, 9:38 AM EST
Completed Not applicable Interventional

Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis

NCT04662008
View directory record Official record
Conditions
Multiple Sclerosis, Caregivers
Interventions
Tele-coaching, Website
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Regional Lung Defect Severity

NCT01640288
View directory record Official record
Conditions
COPD
Interventions
Perfluorinated Gas/Oxygen Mixture, High Resolution CT of the Chest
Drug · Other
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Nov 10, 2026, 9:38 AM EST
Completed No phase listed Observational

ClearWay™ RX Registry Trial

NCT00804024
View directory record Official record
Conditions
Heart Diseases, Vascular Diseases
Interventions
ClearWay™ RX Local Therapeutic Infusion Catheter
Device
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Escondido, California • Washington D.C., District of Columbia • Winter Haven, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Nov 10, 2026, 9:38 AM EST
Withdrawn Phase 2 Interventional

Phase Analysis and Obstructive CAD on Rubidium PET

NCT01840696
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Balloon REmodeling Antrostomy THErapy Study

NCT00645762
View directory record Official record
Conditions
Sinusitis
Interventions
RS-Series Rhinosinusitis Treatment System, FinESS Balloon
Device
Lead sponsor
Entellus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Fresno, California • Evanston, Illinois • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Parasternal Nerve Block in Cardiac Patients

NCT01826851
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Postoperative
Interventions
Exparel, Placebo
Drug
Lead sponsor
Peter A Knight
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 10, 2026, 9:38 AM EST
Recruiting Phase 4 Interventional

Ketamine as a Supplement to Local Anesthesia for Minor Procedures

NCT06284473
View directory record Official record
Conditions
Pain, Procedural, Minor Laceration, Abscess
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Loyola University
Other
Eligibility
7 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Nov 10, 2026, 9:38 AM EST
Recruiting Not applicable Interventional

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection

NCT07700927
View directory record Official record
Conditions
Prosthetic Joint Infection of Knee
Interventions
Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment, Debridement, Antibiotics, Implant Retention
Device · Procedure
Lead sponsor
Solenic Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Albany, Ohio • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic

NCT00508976
View directory record Official record
Conditions
Pain, Postoperative, Morbid Obesity
Interventions
Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision
Drug
Lead sponsor
Pinnacle Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional

R115777 in Treating Patients With Advanced Bladder Cancer

NCT00006376
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Nov 10, 2026, 9:38 AM EST
Recruiting Not applicable Interventional

Closed Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome

NCT06421350
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
Spinal Cord Stimulation Device
Device
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 3 Interventional

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

NCT00002882
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin, Dacarbazine, Vinblastine, Adjuvant Therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

NCT03127943
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Nov 10, 2026, 9:38 AM EST
Suspended Phase 2 Interventional

Ketamine HCl Prolonged Release Oral Tablets for CRPS

NCT06419985
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
80mg/day Ketamine HCl Prolonged Release, 160mg/day Ketamine HCl Prolonged Release
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 10, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Wellness Champions for Change

NCT03432715
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Student Wellness Champions, Teacher Wellness Champions
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
7 Years to 16 Years
Enrollment
2,773 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
Interventions
Bevacizumab, Temsirolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
57
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Nov 10, 2026, 9:38 AM EST
Recruiting Phase 3 Interventional

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

NCT07210515
View directory record Official record
Conditions
Complex Regional Pain Syndrome Type I
Interventions
Neridronate, Placebo
Drug
Lead sponsor
Ambros Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 4 Interventional Results available

Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients

NCT01647282
View directory record Official record
Conditions
Moderate to Advanced Chronic Periodontitis
Interventions
locally-applied minocycline HCl (1 mg), scaling and root planing (Sc/RP)
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 10, 2026, 9:38 AM EST
Completed Not applicable Interventional Results available

TeleQuit Smoking Cessation Program

NCT00123682
View directory record Official record
Conditions
Smoking
Interventions
Proactive outreach to counseling, Reactive outreach to counseling, Intensive counseling, Self-help
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
3,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Palo Alto, California • Sepulveda, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Nov 10, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

NCT00485693
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine HCl, SKY0402
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • Davis, California • Laguna Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 10, 2026, 9:38 AM EST